SCHEMBL1546

SCHEMBL1546

NC(=O)OCC[SiH3]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3789665 0.83
SCHEMBL2547540 0.81 LMNA (0.57)
SCHEMBL30525718 0.78 LMNA (0.62)
SCHEMBL27862143 0.75
Ethylene SCHEMBL21679941 0.75 TSHR (0.52)
SCHEMBL2745809 0.75 LMNA (0.52)
Formaldehyde SCHEMBL4454552 0.75 TSHR (0.52)
SCHEMBL2746597 0.75 TSHR (0.52)
SCHEMBL24835739 0.73 TSHR (0.50)
SCHEMBL5721317 0.73 TSHR (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034810-B2 Matrix metalloproteinase inhibitors; antiinflammatory agengs; rheumatoid arthritis, osteoarthritis; antitumor, anticarcinogenic, and antimetastasis agents; respiratory system disorders, chronic obstructive pulmonary disease, deblocking, deprotecting NOVARTIS AG (CH) 2011-10-11 US disclosed
EP-1202961-B1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES NOVARTIS AG (CH) 2010-01-20 EP disclosed
EP-2085379-A1 Arylsulfonamido-substituted hydroxamic acid derivatives Novartis AG (CH) 2009-08-05 EP disclosed
US-20080275127-A1 Arylsulfonamido-substituted hydroxamic acid derivatives BREITENSTEIN WERNER 2008-11-06 US disclosed
EP-0938486-B1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 2008-01-16 EP disclosed
US-7138432-B1 Arylsulfonamido-substituted hydroxamic acid derivatives NOVARTIS AG (CH) 2006-11-21 US disclosed
US-7091346-B1 Purine derivatives and processes for their preparation NOVARTIS AG (CH) 2006-08-15 US disclosed
EP-0672042-B1 PHARMACOLOGICALLY ACTIVE PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 2006-05-03 EP disclosed
US-6767906-B2 INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. NOVARTIS AG (CH) 2004-07-27 US disclosed
EP-1153024-B1 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS NOVARTIS AG (CH) 2004-04-28 EP disclosed
EP-0239543-A2 Glucose derivatives and methods for their preparation CIBA-GEIGY AG (CH) 1987-09-30 EP disclosed
US-4640911-A IMMUNOSTIMULANTS, VIRICIDES SUCH AS HERPES SIMPLEX CIBA-GEIGY CORPORATION (US) 1987-02-03 US disclosed
EP-0192611-A2 Acylated hexose derivatives and method for their preparation CIBA-GEIGY AG (CH) 1986-08-27 EP disclosed
EP-0188400-A2 Oligopeptides, intermediates and process for their preparation CIBA-GEIGY AG (CH) 1986-07-23 EP disclosed
US-4595677-A Substituted tetrapeptides CIBA-GEIGY CORPORATION (US) 1986-06-17 US disclosed
EP-0174912-A2 Phosphorus compounds, process for their preparations and their use CIBA-GEIGY AG (CH) 1986-03-19 EP disclosed
EP-0169812-A1 Phosphatidyl compounds, process for their preparation and their use CIBA-GEIGY AG (CH) 1986-01-29 EP disclosed
EP-0163286-A2 Acylated sugars, method for their preparation and their use CIBA-GEIGY AG (CH) 1985-12-04 EP disclosed
US-4464366-A Cephem compounds having a terminal aminocarboxylic acid grouping and containing an azacyclyl(thio)ureido group CIBA GEIGY CORPORATION (US) 1984-08-07 US disclosed
US-4423038-A Phosphoryl compounds, pharmaceutical preparations containing such compounds, and their use CIBA-GEIGY CORPORATION (US) 1983-12-27 US disclosed